Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159403 · ClinicalTrials.gov registry record
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
A clinical trial, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- 325
- Enrollment target
NCT03159403 is a clinical trial that has completed, run by Melinta Therapeutics. The registered enrollment target is 325 participants.
The verdict
NCT03159403 has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- 325 participants
- Enrollment target
Study Summary
This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.
Interventions
- DRUG Oritavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2018-03-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03159403
The ClinicalTrials.gov registry entry for NCT03159403 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oritavancin is the first listed.
NCT03159403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03159403 about?
NCT03159403 is a clinical study titled "A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting". This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.
What is the current status of trial NCT03159403?
This trial is currently completed. The enrollment target is 325 participants. The study started on 2017-04-12. Estimated completion is 2018-03-08.
What interventions are being tested in trial NCT03159403?
The interventions under investigation include: Oritavancin (DRUG).
Who is sponsoring clinical trial NCT03159403?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.